Trial Profile

A Phase 3 clinical trial of Niclosamide (Xafty) in high-risk group patients with mild-to-moderate COVID-19

Status: Planning

Phase of Trial: Phase III

Latest Information Update: 29 Aug 2024

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Niclosamide (Primary)
Indications COVID 2019 infections
Focus Therapeutic Use
Sponsors Hyundai Bioscience

Most Recent Events

29 Aug 2024 New trial record
28 Aug 2024 According to a Hyundai Bioscience media release, company announced on Aug 27, it has submitted an Investigational New Drug (IND) application for Phase 3 clinical trial to the Ministry of Food and Drug Safety (MFDS) of the Republic of Korea.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com